Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts

Daniela A. Bota, Jinah Chung, Manisha Dandekar, Jose A. Carrillo, Xiao Tang Kong, Beverly D. Fu, Frank Pk Hsu, Axel H. Schönthal, Florence M. Hofman, Thomas C. Chen, Raphael Zidovetzki, Chrystel Pretto, Ankie Strik, Virgil E.J.C. Schijns, Apostolos Stathopoulos

Research output: Contribution to journalArticleAcademicpeer-review

11 Citations (Scopus)

Fingerprint Dive into the research topics of 'Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts'. Together they form a unique fingerprint.

Medicine & Life Sciences